BioSpace News Archive

Pear Therapeutics, Inc. , the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual panel discussion entitled “Emerging World of Digital Therapeutics” at the SVB Leerink CybeRx Series: Digital Health – Innovators & Disruptors on Thursday, May 21 at 12:35 p.m. Eastern Time. About Pear Therapeutics Pear

CANTEL MEDICAL CORP. (NYSE: CMD) (“Cantel” or the “Company”) today announced the pricing of its offering of $140 million aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A un

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 at 7:00 am Eastern Time on Wednesday, May 20, 2020. Following the release, MediWound’s management will host a conference call and live webcast on Wednesday, May 20, 2020 a

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Wednesday, May 27, 2020 at 8:00 a.m. ET to report interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-sma

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, wit

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 -- -- Presenting Late-Breaking Abstract on Kidney Stone Risk and Association with Urinary Oxalate Levels in Conjunction with AUA Virtual Experience -- NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to devel

• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Poster-SyngeneicMouse_431_ASGCT_Poster_Final-05112020-2.pdf Slide Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Presentation-SyngeneicMouse_431_ASGCT_Final-05112020.pdf - A second study provides

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the first quarter ended March 31, 2020. “We remain keenly focused on executing on our core mission to deliver effective therapies for rare and specialty diseases amidst these unprecedented times,” Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.

I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1/2 clinical study in China to evaluate I-Mab’s proprietary CD73 antibody TJD5

Survey Highlights Opportunities to Leverage Technology to Improve Time-Consuming Administrative Process, Especially While Many Physicians Are Offline or Remote Due to COVID-19